Last reviewed · How we verify
MB0151 for injection — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
MB0151 for injection (MB0151 for injection) — Mainline Biosciences (Shanghai) Co., Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MB0151 for injection TARGET | MB0151 for injection | Mainline Biosciences (Shanghai) Co., Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MB0151 for injection CI watch — RSS
- MB0151 for injection CI watch — Atom
- MB0151 for injection CI watch — JSON
- MB0151 for injection alone — RSS
Cite this brief
Drug Landscape (2026). MB0151 for injection — Competitive Intelligence Brief. https://druglandscape.com/ci/mb0151-for-injection. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing